Medicine
Maxalt-mlt 10 mg orally disintegrating tablet
Maxalt-mlt 10 mg orally disintegrating tablet is a prescription medicine containing Rizatriptan for oral use, marketed by Organon, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store MAXALT Tablets at room temperature, 15°C-30°C (59°F-86°F). Store…
Key facts
- Active ingredient (INN)
- Rizatriptan
- Brand
- Maxalt-mlt
- Strength
- 10 mg
- Dosage form
- Orally disintegrating tablet
- Route
- Oral
- Packs
- 6 containers
- Marketing authorisation holder
- Organon
- Manufacturer
- Organon
- Origin register
- US FDA, United States
- Storage
- Store MAXALT Tablets at room temperature, 15°C-30°C (59°F-86°F). Store MAXALT-MLT Orally Disintegrating Tablets at room temperature, 15°C-30°C (59°F-86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N02CC04 Rizatriptan
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 June 2021
- Identifiers
- RxCUI 314209, 828537, 213322 +1DailyMed set ID 007b4644-e0e7-4863-9ae3-fe09676b3f5fNDC 78206-143Application NDA020865
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 container in 1 carton / 3 pouch in 1 container / 1 blister pack in 1 pouch / 1 tablet, orally disintegrating in 1 blister pack | 78206-143-01 | Organon | 1 June 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 29 June 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Rizatriptan 10 mg orally disintegrating tablet.
Other strengths and forms of Rizatriptan
Clinical summary
Rizatriptan is a serotonin-1b and serotonin-1d receptor agonist indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old, among other approved uses. MedsAcross supplies Rizatriptan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RizatriptanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- MAXALT prescribing information (Organon) · U.S. National Library of Medicine, DailyMed
Need Maxalt-mlt 10 mg orally disintegrating tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.